Last updated on September 2018

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma


Brief description of study

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.

Detailed Study Description

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.

COMPOUND 2055269 has demonstrated meaningful clinical activity across various tumor types and treatment settings. No clinical trial is conducted over COMPOUND 2055269 in locally-advanced rectal adenocarcinoma.

Clinical Study Identifier: NCT03503630

Contact Investigators or Research Sites near you

Start Over

Rim Turfa, M.D.

King Hussein Cancer Center
Amman, Jordan
  Connect »

Ali I Shamseddine, M.D.

American University of Beirut Medical Center
Beirut, Lebanon
  Connect »

Joseph Kattan, M.D.

H tel Dieu de France
Beirut, Lebanon
  Connect »